Journal Mobile Options
Table of Contents
Vol. 35, Suppl. 2, 2013
Issue release date: May 2013
Blood Purif 2013;35(suppl 2):5-13
(DOI:10.1159/000350837)

The Double Polymethylmethacrylate Filter (DELETE System) in the Removal of Light Chains in Chronic Dialysis Patients with Multiple Myeloma

Santoro A. · Grazia M. · Mancini E.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Multiple myeloma (MM) is still one of the most common haematological diseases and is associated with a poor prognosis. It is frequently worsened by acute kidney failure that, in turn, aggravates the risk of death. In the past few years, the idea has made headway that the removal of free light chains (FLC) by means of extracorporeal blood purification systems may facilitate the recovery of renal function. Up to now, many different extracorporeal techniques have been put forward in FLC removal, such as plasma exchange, dialysis with super-flux filters, and adsorption by means of cartridge of resins. In this paper, we illustrate the use of polymethylmethacrylate (PMMA) dialysis membranes with a high adsorptive capacity (Toray BK-F; Toray Industries, Inc., Tokyo, Japan). We have evaluated light chain removal by means of an original dialysis procedure using a double-filter circuit made of PMMA working in sequential dialysis (DELETE system). The system provides satisfactory results in terms of FLC removal and, at the same time, ensures an adequate dialysis treatment (Kt/V >1.5) with significant reduction in urea, creatinine, and β2-microglobulin. The dual PMMA filter system combines an acceptable cost/efficiency ratio when compared with other methods and constitutes a concrete prospect in FLC removal. Its preferential setting of use is in patients with MM or with monoclonal gammopathies, who are on chronic dialysis and maintain high circulating levels of FLC.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kyle RA, Beard CM, O'Fallon WM, Kurland LT: Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol 1994;12:1577-1583.

    External Resources

  2. Tsakiris DJ, Stel VS, Finne P, et al: Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010;25:1200-1206.
  3. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175-1180.
  4. Barosi G, Boccadoro M, Cavo M, et al: Management of multiple myeloma and related disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group of Bone Marrow Transplantation (GITMO). Haematologica 2004;89:717-741.

    External Resources

  5. Clark WF, Stewart AK, Rock GA, et al: Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143:777-784.
  6. Hutchison CA, Cockwell P, Reid S, et al: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-895.
  7. Ludwig H, Drach J, Graf H, et al: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92:1411-1414.
  8. Hutchison CA, Bradwell AR, Cook M, et al: Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-754.
  9. Pasquali S, Mancini E, Santoro A: Removal of free circulating light chains (LC) by a high cutoff membrane: different dialysis strategies. ASN 2008, Philadelphia (USA). J Am Soc Nephrol 2008;19(1560A).
  10. Harding S, Provot F, Beuscart JB, et al: Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant 2011;26:1438-1440.
  11. Pasquali S, De Sanctis LB, Mambelli E, Di Felice A, Wratten M, Santoro A: Coupled plasmafiltration adsorption: a new technology for free light chain removal. ASN 2007, San Francisco (USA). J Am Soc Nephrol 2007;18(252A).
  12. Leung N, Gertz MA, Zeldenrust SR, et al: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282-1288.
  13. Cohen G: Immunoglobulin light chains in uremia. Kidney Int 2003;63(suppl 84):S15-S18.
  14. Vanholder R, Glorieux G, De Smet R, et al: New insights in uremic toxins. Kidney Int Suppl 2003;84:S6-S10.
  15. Birk HW, Kistner A, Wizemann V, Schütterle G: Protein adsorption by artificial membrane materials under filtration. Artif Organs 1995;19:411-415.
  16. Aoike I: Clinical significance of protein adsorbable membranes - long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant 2007;22 (suppl 5):v13-v19.
  17. Santoro A, Guadagni G: Dialysis membrane: from convection to adsorption. NDT Plus 2010;3(suppl 1):i36-i39.

    External Resources

  18. Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-2085.
  19. Campistol JM, Torregrosa JV, Ponz E, Fenollosa B: Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes. Contrib Nephrol 1999;125:76-85.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50